



(51) International Patent Classification:

C07D 519/00 (2006.01) A61K 31/5025 (2006.01)
A61K 31/433 (2006.01) C07D 487/04 (2006.01)
A61K 31/4439 (2006.01) A61P 7/02 (2006.01)
C07D 513/04 (2006.01)

(21) International Application Number:

PCT/US2013/037884

(22) International Filing Date:

24 April 2013 (24.04.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/638,567 26 April 2012 (26.04.2012) US

(71) Applicants: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Route 206 and ProvinceLine Road, Princeton, New Jersey 08543-4000 (US). **UNIVERSITE DE MONTREAL** [CA/CA]; 2900 Edouard-Montpetit Boulevard, Montreal, Québec H3T 1J4 (CA).

(72) Inventors: **PRIESTLEY, Eldon Scott**; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534 (US). **POSY, Shoshana L.**; c/o Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **TREMBLAY, Francois Tremblay**; c/o Universite de Montreal, 2900 Edouard-Montpetit Boulevard, Montreal, Québec H3T 1J4 (CA). **MARTEL, Alain**; c/o Universite de Montreal, 2900, Edouard-Montpetit Boulevard, Montreal, Québec H3T 1J4 (CA). **MARINIER, Anne**; c/o Universite de Montreal, 2900, Edouard-Montpetit Boulevard, Montreal, Québec H3T 1J4 (CA).


(74) Agents: **BOGIE, Terence J.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,


[Continued on next page]

(54) Title: IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION

Fig 1. Human Washed Platelet Aggregation
Induced by 1.5 nM Alpha-Thrombin



(57) Abstract: The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R⁰, R², R⁴, R^a, R^b, X¹, X², X³ and X⁴ are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.





NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*